Posted by Michael Wonder on 11 Oct 2018
Sandoz announces global resolution of biosimilar adalimumab patent disputes, securing patient access
11 October 2018 - Resolution paves way for 2018 launch in key European markets and secures US market entry planned in 2023.
Sandoz today announced a global resolution of all intellectual property related litigation with AbbVie concerning the proposed Sandoz biosimilar Hyrimoz (adalimumab) for reference medicine Humira (adalimumab).
Under the terms of the agreement, AbbVie grants Sandoz a non-exclusive license to AbbVie's intellectual property relating to Humira, beginning on certain dates in certain countries in which AbbVie has intellectual property. The license period will begin on 16 October 2018 in most countries in the European Union, and on other dates in various other countries outside the US where AbbVie has IP. In the US, the license period will begin on 30 September 2023.
